Skip to main content

Table 1 Patient demographic and encounter characteristics

From: Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study

Variable

All candidemia

Fluconazole prophylaxis

No prophylaxis

Pvaluea

(n= 227)

(n= 33)

(n= 194)

Age (years)

62.4 (15.0)

61.7 (13.7)

62.5 (15.2)

0.6188

Female gender

118 (52.0%)

20 (60.6%)

98 (50.5%)

0.2835

Race

    

Caucasian

167 (73.6%)

24 (72.7%)

143 (73.7%)

0.4575

African American

45 (19.8%)

9 (27.3%)

36 (18.6%)

Asian

2 (0.9%)

0 (0.0%)

2 (1.0%)

Other known

9 (4.0%)

0 (0.0%)

9 (4.6%)

Unknown

4 (1.8%)

0 (0.0%)

4 (2.1%)

Admission source

    

Hospital/other care facility

35 (15.4%)

5 (15.2%)

30 (15.5%)

0.1363

SNF/NH

3 (1.3%)

0 (0.0%)

3 (1.5%)

Emergency room

102 (44.9%)

21 (63.6%)

81 (41.8%)

Other

78 (34.4%)

7 (21.2%)

71 (36.6%)

Unknown

9 (4.0%)

0 (0.0%)

9 (4.6%)

Urgent/emergent admission

142 (62.6%)

28 (84.8%)

114 (58.8%)

 

Charlson Comorbidity Index score

2.1 (2.4)

2.4 (2.9)

2.0 (2.3)

0.9624

Comorbid conditions

    

Diabetes

56 (24.7%)

10 (30.3%)

46 (23.7%)

0.4168

Hypertension

83 (36.6%)

10 (30.3%)

73 (37.6%)

0.4192

Coronary artery disease

29 (12.8%)

7 (21.2%)

22 (11.3%)

0.1163

Heart failure

32 (14.1%)

6 (18.2)

26 (13.4%)

0.4657

Prior stroke/TIA

12 (5.3%)

5 (15.2%)

7 (3.6%)

0.0062

COPD/bronchiectasis

36 (15.9%)

6 (18.2%)

30 (15.5%)

0.6927

Encounter events

    

Bacteremia during index encounter

94 (41.4%)

18 (54.5%)

76 (39.2%)

0.0975

ICU exposure during index encounter

135 (59.5%)

30 (90.9%)

105 (54.1%)

<0.0001

Respiratory failure prior to positive BCx for Candida

154 (67.8)

25 (75.8)

129 (66.5)

0.2923

IV vasopressor prior to positive BCx for Candida

123 (54.2)

24 (72.7)

99 (51.0)

0.0207

Baseline laboratory parameters

    

WBC (k/mm3)

12.8 (8.6)

13.2 (11.2)

12.7 (8.1)

0.597

Neutropenia (ANC <500 cells/mm3) any time

27 (11.9%)

9 (27.3%)

18 (9.3%)

0.0181

Blood glucose (mg/dl)

146.5 (72.2)

145.4 (66.4)

146.7 (73.3)

0.8315

eGFR (ml/minute/1.73 m2)

65.4 (45.8)

69.8 (69.0)

64.6 (40.7)

0.8255

Time from presentation to positive BCx for Candida draw

   

< 48 hours

16 (7.0%)

1 (3.0%)

15 (7.7%)

0.1914

48 to 96 hours

12 (5.3%)

0 (0%)

12 (6.2%)

> 96 hours

199 (87.8%)

32 (97.0%)

167 (86.1%)

Time from presentation to initial procedure of interest

   

On the day of admission

70 (30.8%)

10 (30.3%)

60 (30.9%)

0.5945

1 to 2 days

44 (19.4%)

7 (21.2%)

37 (19.1%)

≥3 days

113 (49.8%)

16 (48.5%)

97 (50.0%)

Antifungal therapy within 30 days prior to admission

3 (1.3%)

1 (3.0%)

2 (1.0%)

0.3525

  1. Data presented as mean (standard deviation) or number (percentage). ANC, absolute neutrophil count; BCx, blood culture; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; IV, intravenous; SNF/NH, skilled nursing facility/nursing home; TIA, transischemic attack; WBC, white blood cell count. aP value for the comparison between fluconazole prophylaxis and nonprophylaxis.